BET in hematologic tumors:Immunity,pathogenesis,clinical trials and drug combinations  

作　　者：Tao Ma Yan Chen Zhi-Gang Yi Yan-Hong Li Jun Bai Li-Juan Li Lian-Sheng Zhang 

机构地区：[1]Department of Hematology,The Affiliated Hospital of Southwest Medical University,Luzhou,Sichuan 646000,China [2]Department of Hematology,Lanzhou University Second Hospital,Lanzhou,Gansu 730000,China

出　　处：《Genes & Diseases》2023年第6期2306-2319,共14页基因与疾病（英文）

基　　金：supported by grants from Cuiying Technology Innovation Project of Lanzhou University Second Hospital(China)(No.CY2017-ZD04 and CY2019-MS14);Commissioned Project of National Clinical Medicine Research Center for Hematological System Diseases(China)(No.2021WWA01);Talent Innovation and Entrepreneurship Project of Lanzhou,China(No.2020-RC-48).

摘　　要：The bromodomain and extra-terminal(BET)proteins act as“readers”for lysine acetylation and facilitate the recruitment of transcriptional elongation complexes.BET protein is associated with transcriptional elongation of genes such as c-MYC and BCL-2,and is involved in the regulation of cell cycle and apoptosis.Meanwhile,BET inhibitors(BETi)have regulatory effects on immune checkpoints,immune cells,and cytokine expression.The role of BET proteins and BETi in a variety of tumors has been studied.This paper reviews the recent research progress of BET and BETi in hematologic tumors(mainly leukemia,lymphoma and multiple myeloma)from cellular level studies,animal studies,clinical trials,drug combination,etc.BETi has a promising future in hematologic tumors,and future research directions may focus on the combination with other drugs to improve the efficacy.

关 键 词：BET BRD4 Clinical trials Hematologic tumors IMMUNITY MYC 

分 类 号：R73[医药卫生—肿瘤]